Stock Financial Ratios and Split History
CBIO / Catalyst Biosciences Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||19.62|
|Enterprise Value ($M)||-28.45|
|Book Value ($M)||16.07|
|Book Value / Share||16.07|
|Price / Book||4.94|
|NCAV / Share||20.70|
|Price / NCAV||4.87|
|Income Statement (mra) ($M)|
|Balance Sheet (mrq) ($M)|
|Cash & Equivalents||10.97|
|Cash / Share||10.97|
|Preferred Stock Shares Outstanding||0|
|Common Shares Outstanding||1,000,036|
|Common Stock Shares Outstanding||801,756|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Cash Conversion Cycle||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-1.05|
|Return on Assets (ROA)||-0.44|
|Return on Equity (ROE)||-1.05|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1124105|
|SIC 2834 - Pharmaceutical Preparations|
|14888D959 14888D958 14888D909 14888D208|
Stock splits are used by Catalyst Biosciences Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
Peers - Pharmaceutical Preparations (2834)
ENDV / Endonovo Therapeutics, Inc.
AXIM / Axim Biotechnologies, Inc.
PRTT / Protect Pharmaceutical Corp
NNAB / NanoAntibiotics, Inc.
Related News Stories
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment. (727-5)
Chicago, IL – March 9, 2018 - Stocks in this week’s article Unisys Corporation (UIS - Free Report) , Catalyst Biosciences, Inc. (CBIO - Free Report) , Liberty Ventures (LVNTA - Free Report) and New Mountain Finance Corporation (NMFC - Free Report) . (16-0)
Coverage initiation on a stock by analyst(s) plays a significant role in interpreting information pertaining to capital markets, thereby creating value for investors. Lack of information creates inefficiencies that might trigger misinterpretation of stocks (over- or under-valued). (16-0)
Coverage initiation on a stock by analyst(s) plays a significant role in interpreting information pertaining to capital markets, thereby creating value for investors. Lack of information creates inefficiencies that might trigger misinterpretation of stocks (over- or under-valued). In fact, coverage initiation usually depicts increased investor inclination. Investors, on their part, often assume that there is something in the stock that has attracted analyst attention. (16-0)
Catalyst Biosciences reported positive phase 1/2 data in patients with Hemophiila B using its treatment known as CB 2679d. (51-3)